Drug Interactions with Tobacco Smoke: Implications for Patient Care

Martha P. Fankhauser

Current psychiatry · 2013 · 12 citations · 3 references

Concepts

Abstract

Mrs. C, age 51, experiences exacerbated asthma and difficulty breathing and is admitted to a non-smoking hospital. She also has chronic obstructive pulmonary disease, type 2 diabetes mellitus, hypertension, hypercholesterolemia, hypothyroidism, gastroesophageal reflux disease, overactive bladder, muscle spasms, fibromyalgia, bipolar disorder, insomnia, and nicotine and caffeine dependence. She takes 19 prescribed and over-the-counter medications, drinks up to 8 cups of coffee per day, and smokes 20 to 30 cigarettes per day. In the emergency room, she receives albuterol/ipratropium inhalation therapy to help her breathing and a 21-mg nicotine replacement patch to avoid nicotine withdrawal. [ILLUSTRATION OMITTED] In the United States, 19% of adults smoke cigarettes.' Heavy tobacco smoking and nicotine dependence are common among psychiatric patients and contribute to higher rates of tobacco-related morbidity and mortality.2 When smokers stop smoking or are admitted to smoke-free facilities and are forced to abstain, nicotine withdrawal symptoms and changes in drug metabolism can develop over several days. (3-5) Smokers such as Mrs. C are at risk for cytochrome (CYP) P450 drug interactions when they are admitted to or discharged from a smoke-free facility Nine of Mrs. C's medications are substrates of CYP1A2 (acetaminophen, caffeine, cyclobenzaprine, diazepam, duloxetine, melatonin, olanzapine, ondansetron, and zolpidem). When Mrs. C stops smoking while in the hospital, she could experience higher serum concentrations and adverse effects of these medications. If Mrs. C resumes smoking after bring discharged, metabolism and dearance of any medications started while she was hospitalized that are substrates of CYP1A2 enzymes could be increased, which could lead to reduced efficacy and poor clinical outcomes. Pharmacokinetic effects Polycyclic aromatic hydrocarbons in tobacco smoke induce hepatic CYP1A1, 1A2, and possibly 2E1 isoenzymes.sup. (6-12) CYP1A2 is a hepatic enzyme responsible for metabolizing and eliminating several classes of substrates (eg, drugs, hormones, endogenous compounds, and procarcinogens). (6), (13) Genetic, epigenetic, and environmental factors such as smoking impact the expression and activity of CYP1A2 and result in large interpatient variability in pharmacokinetic drug interactions. (6), (12), (13) CYP1A2 enzymes can be induced or inhibited by drugs and substances, which can result in decreased or increased serum concentrations of substrates, respectively. When individuals stop smoking and switch to other nicotine products or devices, CYP1A2 induction of hepatic enzymes will revert to normal metabolism over several weeks to a month. (10) Besides tobacco smoke, other CYP1A2 inducers include charbroiled food, carbamazepine, omeprazole, phenobarbital, primidone, and rifampin (4), (5) Nicotine replacement products-such as gum, inhalers, lozenges, patches, and nasal spray-and nicotine delivery devices such as electronic cigarettes do not induce hepatic CYP1A2 enzymes or cause the same drug interactions as cigarette smoking. Table 1 (3-11) and Table 2 (page 14) (3-11) list commonly prescribed CYP1A2 substrates that could be affected by tobacco smoke. There are no specific guidelines for how to assess, monitor, or manage pharmacokinetic drug interactions with tobacco smoke. (6-3) Induction of hepatic CYP1A2 enzymes by cigarette smoke may require increased dosages of some psychotropics--such as tricyclic antidepressants, duloxetine, mirtazapine, and some first- and second-generation antipsychotics (SGAs)--to achieve serum concentrations adequate for clinical efficacy. Serum concentrations may increase to toxic levels and result in adverse effects when a person quits smoking cigarettes or if a CYP1A2 inhibitor, such as amlodipine, cimetidine, ciprofloxacin, diclofenac, fluoxetine, fluvoxamine, or nifedipine, is added. (5) Table 1 Common major cytochrome P450 (CYP) 1A2 substrates Alosetron (3), (5), (6) Irritable bowel syndrome: serotonin 3 antagonist Aminophylline (3), (5) Bronchodilator: theophylline derivative Betaxolol (3), (5) [beta]-1 selective adrenergic receptor blocking agent Caffeine (3-9) Stimulant Clomipramine (3-11) Tricyclic antidepressant Clozapine (3-10) Second-generation antipsychotic Cyclobenzaprine (3-7) Skeletal muscle relaxant Doxepin (3), (7), (10), (11) Tricyclic antidepressant Duloxetine (3-6) Serotonin-norepinephrine reuptake inhibitor Estradiol (3), (5-8) Estrogen (active) Estrogens: conjugated and Estrogen (derivatives) estropipate (3), (5); estrone(3), (7) Fluvoxamine (3), (8), (9) Selective serotonin reuptake inhibitor Guanabenz (3), (5-7) [alpha] -2 adrenergic agonist Mirtazapine (3-7) Antidepressant: a-2 agonist/serotonin 2A, 2C antagonist Olanzapine (3-11) Second-generation antipsychotic Pimozide (3), (5), (7) First-generation antipsychotic Propranolol (3-11) [beta] -adrenergic blocker Ramelteon (3), (5), (10) Melatonin receptor agonist Rasagiline (3), (5) Antiparkinson: type B monoamine oxidase inhibitor Riluzole (3-7) (10) Glutamate inhibitor Ropinirote (3), (5-7) Antiparkinson: dopamine agonist Theophylline (3-6), (8-11) Bronchodilator: methylxanthine Thiothixene (3), (5) First-generation antipsychotic Trifluoperazine (3), (5), First-generation (9) antipsychotic Several classes of CYP1A2 substrates are not included and may cause toxicity with smoking cessation or require dosage increases in tobacco smokers (eg, antiarrhythmic, antifungal, antimalarial, antineoplastic, antiretroviral, and anthelmintic agents and the antibiotic quinolone). …

References

3